secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001140361-26-019205
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore Q1 KIMMTRAK net sales $106.7M (+14% YoY); net income $13M vs $5M
---------------------------------------------------------------------------

- KIMMTRAK net sales $106.7M, up 14% YoY; US sales $67.4M (+19.1% YoY), Europe $34.4M.
- Net income $13.0M ($0.25 diluted EPS) vs $5.0M ($0.10) in Q1 2025.
- Five-year OS data at AACR: KIMMTRAK OS rate 16% vs 8% control in metastatic uveal melanoma (HR 0.67).
- Cash and marketable securities $845M; R&D expense $61.1M, SG&A $37.9M.
- Phase 3 TEBE-AM (cutaneous melanoma) enrollment expected to complete H1 2026; topline data H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/0001140361-26-019205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000114036126019205/ef20072537_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-019205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer